BridgeBio Encaleret NDA Accepted, PDUFA May 2027

BridgeBio Pharma (BBIO) announced on July 22, 2026 that the FDA accepted for filing its New Drug Application for encaleret, an oral therapy for autosomal dominant hypocalcemia type 1 (ADH1). The FDA assigned a PDUFA target action date of May 8, 2027, and is not currently planning an advisory committee meeting.

What ADH1 is

ADH1 is an ultra-rare genetic disorder caused by gain-of-function mutations in the calcium-sensing receptor gene. The mutation causes the body to inappropriately suppress parathyroid hormone production, leading to low blood calcium, excessive urinary calcium excretion, kidney damage, muscle cramps, and seizures. There are no FDA-approved treatments specifically for ADH1. More than 2,100 individuals have been diagnosed in the U.S. since October 2023, a number that likely undercounts the true prevalence given how often the condition goes unrecognized.

Patients typically cycle through multiple specialists before anyone connects their symptoms to ADH1. Current management relies on calcium and active vitamin D supplements, which can worsen the urinary calcium excretion that drives kidney damage over time.

The drug and the trial

Encaleret is an oral small molecule that selectively modulates the calcium-sensing receptor. The NDA is based on the Phase 3 CALIBRATE trial, which met all prespecified primary and key secondary efficacy endpoints. The trial showed encaleret normalized key markers of calcium-sensing receptor-driven disease biology without the need for calcium and vitamin D supplements, with a favorable safety profile.

Additional data presented at the European Congress of Endocrinology 2026 and the Endocrine Society annual meeting showed simultaneous restoration of blood and urine calcium levels and restoration of physiologic parathyroid hormone production.

Encaleret has received Fast Track Designation and Orphan Drug Designation in the U.S., European Union, and Japan. BridgeBio also plans to submit a European Marketing Authorization Application in the second half of 2026.

Why the no-adcom signal matters

The FDA’s decision not to hold an advisory committee meeting is a positive signal. Advisory committees are convened when the FDA wants outside expert input on questions about efficacy, safety, or trial design. Skipping adcom typically means the agency is comfortable with the data package and does not see issues requiring external deliberation.

For a first-in-class therapy in an ultra-rare disease with no approved treatments, this suggests the CALIBRATE data is clean enough that the FDA does not anticipate controversy. It does not guarantee approval, but it removes a potential hurdle.

BBIO closed at $82.93 on July 22 with a market cap of approximately $16.2 billion. BridgeBio calls encaleret a potential blockbuster, meaning $1 billion-plus in annual revenue. That is a stretch for 2,100 diagnosed patients, but the count is growing and no competitor exists. At $300,000 to $500,000 per patient annually, the diagnosed population alone could support $630 million to $1.05 billion. The RECLAIM-HP trial in chronic hypoparathyroidism would add to that.

What to watch next

The risk factor is the 10-month wait until the May 2027 PDUFA date. During that window, the FDA could reverse its no-adcom position if review questions emerge. BridgeBio is also enrolling CALIBRATE-PEDS, a Phase 2/3 study in pediatric ADH1.

For context on FDA drug application reviews, see our coverage of Madrigal’s resmetirom PDUFA.

Source: BridgeBio press release | StockTitan 8-K filing